Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Interest Expenses (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Interest Expenses for 4 consecutive years, with $702000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 10.46% to $702000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 24.2% year-over-year, with the annual reading at $2.8 million for FY2025, 24.2% down from the prior year.
  • Interest Expenses for Q4 2025 was $702000.0 at TScan Therapeutics, roughly flat from $699000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $982000.0 in Q3 2023, with the low at $201000.0 in Q3 2022.
  • Average Interest Expenses over 4 years is $811214.3, with a median of $902000.0 recorded in 2023.
  • The sharpest move saw Interest Expenses skyrocketed 388.56% in 2023, then decreased 29.2% in 2025.
  • Over 4 years, Interest Expenses stood at $975000.0 in 2022, then fell by 12.62% to $852000.0 in 2023, then fell by 7.98% to $784000.0 in 2024, then decreased by 10.46% to $702000.0 in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $702000.0, $699000.0, and $689000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.